Michelle A Lawson
Overview
Explore the profile of Michelle A Lawson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrop R, Blount D, Khan N, Soyombo M, Moyce L, Drayson M, et al.
Mol Cancer Ther
. 2024 Oct;
24(1):93-104.
PMID: 39387839
Chimeric antigen receptor (CAR) T cells represent a novel targeted approach to overcome deficits in the ability of the host immune system to detect and subsequently eradicate tumors. The identification...
2.
Hodgson K, Orozco-Moreno M, Goode E, Fisher M, Garnham R, Beatson R, et al.
EBioMedicine
. 2024 May;
104:105163.
PMID: 38772281
Background: Bone metastasis is a common consequence of advanced prostate cancer. Bisphosphonates can be used to manage symptoms, but there are currently no curative treatments available. Altered tumour cell glycosylation...
3.
Diaz-delCastillo M, Palasca O, Nemler T, Thygesen D, Chavez-Saldana N, Vazquez-Mora J, et al.
J Neurosci
. 2023 Jun;
43(29):5414-5430.
PMID: 37286351
Multiple myeloma (MM) is a neoplasia of B plasma cells that often induces bone pain. However, the mechanisms underlying myeloma-induced bone pain (MIBP) are mostly unknown. Using a syngeneic MM...
4.
Tazzyman S, Stewart G, Yeomans J, Linford A, Lath D, Conner J, et al.
Viruses
. 2023 Mar;
15(3).
PMID: 36992311
Multiple myeloma remains largely incurable due to refractory disease; therefore, novel treatment strategies that are safe and well-tolerated are required. Here, we studied the modified herpes simplex virus HSV1716 (SEPREHVIR),...
5.
Tippett V, Tattersall L, Ab Latif N, Shah K, Lawson M, Gartland A
Oncogene
. 2022 Nov;
42(4):259-277.
PMID: 36434179
Over the last 40 years osteosarcoma (OS) survival has stagnated with patients commonly resistant to neoadjuvant MAP chemotherapy involving high dose methotrexate, adriamycin (doxorubicin) and platinum (cisplatin). Due to the...
6.
Tattersall L, Shah K, Lath D, Singh A, Down J, De Marchi E, et al.
J Bone Oncol
. 2022 Mar;
31:100398.
PMID: 35340569
Background: Osteosarcoma (OS) is the most common type of primary bone cancer affecting children and adolescents. OS has a high propensity to spread meaning the disease is often incurable and...
7.
Andrews R, Brown J, Lawson M, Chantry A
J Clin Med
. 2021 Sep;
10(17).
PMID: 34501423
Lytic bone disease remains a life-altering complication of multiple myeloma, with up to 90% of sufferers experiencing skeletal events at some point in their cancer journey. This tumour-induced bone disease...
8.
Diaz-delCastillo M, Chantry A, Lawson M, Heegaard A
Semin Cell Dev Biol
. 2020 Nov;
112:49-58.
PMID: 33158730
Multiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation,...
9.
Crawford L, Campbell D, Morgan J, Lawson M, Down J, Chauhan D, et al.
Oncogene
. 2020 Jun;
39(27):5001-5014.
PMID: 32523091
Proteasome inhibitors have provided a significant advance in the treatment of multiple myeloma (MM). Consequently, there is increasing interest in developing strategies to target E3 ligases, de-ubiquitinases, and/or ubiquitin receptors...
10.
Marino S, Carrasco G, Li B, Shah K, Lath D, Sophocleous A, et al.
Calcif Tissue Int
. 2020 Apr;
107(1):72-85.
PMID: 32285169
Multiple myeloma (MM) patients develop osteolysis characterised by excessive osteoclastic bone destruction and lack of osteoblast bone formation. Pharmacological manipulation of monoacylglycerol lipase (MAGL), an enzyme responsible for the degradation...